
|Videos|May 7, 2021
Analyzing 24-month data of the PALADIN study
Author(s)David Hutton, OT Staff Reports
Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
Advertisement
Michael A. Singer, MD, of the Medical Center Ophthalmology Associates in San Antonio, Texas, speaks on the highlights of his presentation focusing on intraocular pressure (IOP) in the PALADIN 24-month data intravitreal steroid (ILUVIEN), presented during ARVO 2021.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities
3
ChatGPT-5 overestimates macular hole surgery success, study finds
4
Personalized Treatment with Faricimab in Retinal Vascular Diseases
5


























